Peptidomimetic antagonist of the integrin α(v)β3 inhibits leydig cell tumor growth and the development of hypercalcemia of malignancy

Cancer Research

Volumn 58, Issue 9, 1998, Pages 1930-1935

  Carron, Christopher P ^a   Meyer, Debra M ^a   Pegg, Jodi A ^a   Engleman, V Wayne ^a   Nickols, Maureen A ^a   Settle, Steven L ^a   Westlin, William F ^a   Ruminski, Peter G ^a   Nickols, G Allen ^a  

^a MONSANTO COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BETA [[2 2 [[[3 [(AMINOIMINOMETHYL)AMINO]PHENYL]CARBONYL]AMINO]ACETYL]AMINO] 3,5 DICHLOROBENZENEPROPANOIC ACID; FIBRINOGEN; INTEGRIN; INTEGRIN ALPHA(V)BETA3; MINOCYCLINE; THROMBOCYTE RECEPTOR; THROMBOCYTE RECEPTOR ALPHA2BBETA3; UNCLASSIFIED DRUG; VITRONECTIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CORNEA NEOVASCULARIZATION; FEMALE; HYPERCALCEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; LEYDIG CELL TUMOR; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SCID MOUSE; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH;

ANIMALS; CELL DIVISION; CELLS, CULTURED; CORNEAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYPERCALCEMIA; LEYDIG CELL TUMOR; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM TRANSPLANTATION; PHENYLPROPIONATES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VITRONECTIN; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 0032080854     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Folkman, J., and Ingber, D. Inhibition of angiogenesis. Semin. Cancer Biol., 3: 89-96, 1992.
2. Blood, C. H., and Zetter, B. R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta, 1032: 89-118, 1990.
3. D'Amore, P. A. Capillary growth: a two-cell system. Semin. Cancer Biol., 3: 49-56, 1992.
4. Sunderkotter, C., Steinbrink, K., Goebeler, M., Bhardwaj, R., and Sorg, C. Macrophages and angiogenesis. J. Leukocyte Biol., 55: 410-422, 1994.
5. Bischof, P., Haenggeli, L., and Campana, A. Effect of leukemia inhibitory factor on human cytotrophoblast differentiation along the invasive pathway. Am. J. Reprod. Immunol., 34: 225-230, 1995.
6. Stromblad, S., and Cheresh, D. A. Cell adhesion and angiogenesis. Trends Cell Biol., 6: 462-468, 1996.
7. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79: 1157-1164, 1994.
8. 3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell Sci., 108: 2655-2661, 1995.
9. Varner, J. A., and Cheresh, D. A. Integrins and cancer. Curr. Opin. Cell Biol., 8: 724-730, 1996.
10. 3 integrin complex on human microvascular endothelial cells. J. Invest. Dermatol., 103: 295-299, 1994.
11. Enenstein, J., Waleh, N. S., and Kramer, R. H. Basic FGF and TGF-β differentially modulate integrin expression of human microvascular endothelial cells. Exp. Cell Res., 203: 499-503, 1992.
12. Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., and Cheresh, D. A. Definition of two angiogenic pathways by distinct "v" integrins. Science (Washington DC), 270: 1500-1502, 1995.
13. 3 for angiogenesis. Science (Washington DC), 264: 569-571, 1994.
14. 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest., 96: 1815-1822, 1995.
15. Yatohgo, T., Izumi, M., Kashiwagi, H., and Hayashi, M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct. Funct., 13: 281-293, 1988.
16. 1 in promoting cellular attachment and spreading on fibronectin. J. Cell Biol., 111: 2795-2800, 1990.
17. 3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest., 99: 2284-2292, 1997.
18. Pytela, R., Pierschbacher, M. D., Argraves, S., Suzuki, S., and Ruoslahti, E. Arginine-glycine-aspartic acid adhesion receptors. Methods Enzymol., 144: 475-489, 1987.
19. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 91: 4082-4085, 1994.
20. Scroggs, M. W., Proia, A. D., Smith, C. F., Halperin, E. C., and Klintworth, G. K. The effect of total-body irradiation on corneal neovascularization in the Fischer 344 rat after chemical cauterization. Invest. Ophthalmol. Visual Sci., 32: 2105-2111, 1991.
21. 3. Imp. Adv. Oncol., 1996: 69-87, 1996.
22. Sica, D. S., Martodam, R. R., Aronow, J., and Mundy, G. R. The hypercalcemic rat Leydig cell tumor: a model of the hypercalcemia of malignancy. Calcif. Tissue Int., 35: 287-293, 1983.
23. Folkman, J. The role of angiogenesis in tumor growth. Semin. Cancer Biol., 3: 65-71, 1992.
24. Leek, R. D., Harris, A. L., and Lewis, C. E. Cytokine networks in solid human tumors: regulation of angiogenesis. J. Leukocyte Biol., 56: 423-435, 1994.
25. Bischoff, J. Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell Biol., 5: 69-74, 1995.
26. Auerbach, W., and Auerbach, R. Angiogenesis inhibition: a review. Pharmacol. Ther., 63: 265-311, 1994.
27. Pytela, R., Pierschbacher, M. D., Ginsberg, M. H., Plow, E. F., and Ruoslahti, E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science (Washington DC), 231: 1559-1562, 1986.
28. Coller, B. S., Folts, J. D., Smith, S. R., Scudder, L. E., and Jordan, R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation, 80: 1766-1774, 1989.
29. Crippes, B. A., Engleman, V. A., Settle, S. L., Delarco, J., Ornberg, R. L., Helfrich, M. H., Horton, M. A., and Nickols, G. A. Antibody to β3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology, 137: 918-924, 1996.
30. van den Bogert, C., Dontje, B. H. J., and Kroon, A. M. Arrest of in vivo growth of solid Leydig cell tumor by prolonged inhibition of mitochondrial protein synthesis. Cancer Res., 43: 2247-2251, 1983.
31. 1-phase of the cell cycle. Cancer Lett., 32: 41-51, 1986.
32. Tamargo, R. J., Bok, R. A., and Brem, H. Angiogenesis inhibition by minocycline. Cancer Res., 51: 672-675, 1991.
33. Sipos, E. P., Tamargo, R. J., Weingart, J. D., and Brem, H. Inhibition of tumor angiogenesis. Ann. NY Acad. Sci., 732: 263-272, 1994.
34. Sotomayor, E. A., Teicher, B. A., Schwartz, G. N., Holden, S. A., Menon, K., Herman, T. S., and Frei, E. D. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Cancer Chemother. Pharmacol., 30: 377-384, 1992.
35. Teicher, B. A., Sotomayor, E. A., and Huang, Z. D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res., 52: 6702-6704, 1992.
36. Guerin, C., Laterra, J., Masnyk, T., Golub, L. M., and Brem, H. Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. Biochem. Biophys. Res. Commun., 188: 740-745, 1992.
37. Ingber, D. Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis. J. Cell. Biochem., 47: 236-241, 1991.
38. Leavesley, D. I., Ferguson, G. D., Wayner, E. A., and Cheresh, D. A. Requirement of the integrin β3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J. Cell Biol., 117: 1101-1107, 1992.
39. 1-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J. Cell Biol., 121: 163-170, 1993.
40. Kellihan, M. J., and Mangino, P. D. Pamidronate. Ann. Pharmacother., 26: 1262-1269, 1992.
41. Bilezikian, J. P. Management of acute hypercalcemia. N. Engl. J. Med., 326: 1196-1203, 1994.
42. Body, J. J., Coleman, R. E., and Piccart, M. Use of bisphosphonates in cancer patients. Cancer Treat. Rev., 22: 265-287, 1996.
43. Rice, B. F., Ponthier, R. L., and Miller, M. C. Hypercalcemia and neoplasia: a model system. Endocrinology, 88: 1210-1216, 1971.
44. Rice, B. F., Roth, L. M., Cole, F. E., MacPhee, A. A., Davis, K., Ponthier, R. L., and Sternberg, W. H. Hypercalcemia and neoplasia. Biologic, biochemical, and ultra-structural studies of a hypercalcemia-producing Leydig cell tumor of the rat. Lab. Invest., 33: 428-439, 1975.
45. Berger, M. E., Golub, M. S., Sowers, J. R., Brickman, A. S., Nyby, M., Troyer, H., Rude, R. K., Singer, F. R., Horst, R., and Deftos, L. J. Hypercalcemia in association with a Leydig cell tumor in the rat: a model for tumor-induced hypercalcemia in man. Life Sci., 30: 1509-1515, 1975.
46. 1 integrins. J. Biol. Chem., 268: 16737-16745, 1993.
47. 3 potentiate bone resorption. J. Biol. Chem., 268: 9901-9907, 1993.
48. Horton, M. A., Taylor, M. L., Arnett, T. R., and Helfrich, M. H. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp. Cell Res., 195: 368-375, 1991.